WO2023002443 - SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS
National phase entry:
Publication Number
WO/2023/002443
Publication Date
26.01.2023
International Application No.
PCT/IB2022/056778
International Filing Date
22.07.2022
Title **
[English]
SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS
[French]
COMPOSÉS DE PYRIDONE SUBSTITUÉS UTILES POUR TRAITER DES INFECTIONS À ORTHOMYXOVIRUS
Applicants **
NOVARTIS AG
Inventors
BLOOMFIELD, Graham Charles
HESSE, Matthew James
HUANG, Richard Yichong
MASER, Michael Robert
SUTTON, James
TAFT, Benjamin Robert
TULLY, David Charles
Priority Data
63/224,691
22.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 12406 | |
| EPO | Filing, Examination, Granting | 344703 | |
| Japan | Filing, Examination, Granting | 5939 | |
| South Korea | Filing, Examination, Granting | 18070 | |
| USA | Filing, Examination, Granting | 120490 |
Total:
501,608
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.[French]
L'invention concerne des composés de formule (I) : L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, et des méthodes d'utilisation des composés et des compositions pharmaceutiques pour le traitement de certains troubles viraux, notamment la grippe.